Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB

Blood (2015) 126 (23): 2669.

https://doi.org/10.1182/blood.V126.23.2669.2669

Published: 2015

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Barrans Sharon, PhD, Andrew J Davies, MRCP, Ming Wang, Ming-Qing Du, MB, PhD, Christoph Mamot, MD, Keith Pugh, PhD, Josh Caddy, Matthew A Care, PhD, Jan Taylor, Reuben M Tooze, PhD FRCP, Tom Maishman, Louise Stanton, PhD, Debbie Hamid, Andrew McMillan, PhD, Paul Fields, MD PhD, Andrew Jack, PhD MB, Peter Johnson, MD

Blood (2015) 126 (23): 331.

https://doi.org/10.1182/blood.V126.23.331.331

Published: 2015

Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD

Blood (2015) 126 (23): 2663.

https://doi.org/10.1182/blood.V126.23.2663.2663

Published: 2015

Journal Articles

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Kirit M Ardeshna, MD, Peter Hoskin, Paul Smith, PhD, Nicholas Chadwick, Nivette Braganca, Wai-Lup Wong, MD, Irfan Kayani, Bal Sanghera, Patricia Diez, Helen Lucraft, Andrew Jack, PhD, MB, Christopher J McNamara, George Mikhaeel, MD, Scott Marshall, MD, Ruth Pettengell, Robert E. Marcus, MBBS, FRCP, FRCPath, Anton Kruger, David C Linch, MD FMedSci

Blood (2012) 120 (21): 1621.

https://doi.org/10.1182/blood.V120.21.1621.1621

Published: 2012

Journal Articles

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

Ruth M de Tute, Eve Roman, Andrew Jack, PhD, MB, Roger G Owen, MD, Andy Rawstron, PhD

Blood (2011) 118 (21): 2652.

https://doi.org/10.1182/blood.V118.21.2652.2652

Published: 2011

Journal Articles

Meta-Analysis of Diffuse Large B-Cell Lymphoma Gene Expression Identifies Novel and Recurrent Biological Connections,

Matthew Care, PhD, Sharon Barrans, PhD, Lisa Worrillow, Andrew Jack, PhD, MB, David Westhead, PhD, Reuben Tooze, PhD

Blood (2011) 118 (21): 3682.

https://doi.org/10.1182/blood.V118.21.3682.3682

Published: 2011

Journal Articles

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

Simon Rule, MD, Paul Smith, Peter W Johnson, MD, Simon Bolam, MD, George A Follows, Jo Gambell, Peter Hillmen, MBChB, PhD, Andrew Jack, PhD, MB, Stephen A. N. Johnson, MBBS, FRCP, FRCPath, Amy Kirkwood, Anton Kruger, MBChB, FRCP, FRCPath, John F. Seymour, MD, PhD, Milena Toncheva, Jan Walewski, MD, PhD, David C Linch, MD FMedSci

Blood (2011) 118 (21): 440.

https://doi.org/10.1182/blood.V118.21.440.440

Published: 2011

Journal Articles

A Unified Prognostic Model for Myelodysplastic Syndrome and Acute Myeloid Leukaemia Based on Flow Cytometric Blast Count

Alexandra Smith, BSc PhD, Simon Crouch, MA PhD, Dan Painter, Eve Roman, Matt Cullen, Fiona Bennett, Catherine Cargo, MB, MRCP, Andrew Jack, PhD, MB

Blood (2011) 118 (21): 1736.

https://doi.org/10.1182/blood.V118.21.1736.1736

Published: 2011

Journal Articles

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

Andy C Rawstron, PhD, Chi Doughty, PhD, Ruth M de Tute, Fiona Bennett, Selina Denman, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Andrew Jack, PhD, MB

Blood (2010) 116 (21): 2002.

https://doi.org/10.1182/blood.V116.21.2002.2002

Published: 2010

Journal Articles

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

Catherine Thieblemont, MD, Josette Briere, MD, Nicolas Mounier, Hans-Ullrich Voelker, Wendy Cuccini, Edouard Hirchaud, Andreas Rosenwald, Andrew Jack, PhD, MB, Christer Sundstrom, MD, PhD, Sergio Cogliatti, Phlippe Trougouboff, Ludmila Boudova, Jean Soulier, Remi Houlgatte, Norbert Schmitz, MD, Philippe Gaulard, Christian Gisselbrecht, MD

Blood (2010) 116 (21): 993.

https://doi.org/10.1182/blood.V116.21.993.993

Published: 2010

Journal Articles

Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

Blood (2010) 116 (21): 432.

https://doi.org/10.1182/blood.V116.21.432.432

Published: 2010

Journal Articles

TP53 Deletion in CLL: The Significance of Borderline Level Deletion

Sheila J.M. O’Connor, PhD, Kathryn R Turner, MSc, Bradley Dickinson, MSc, Sharon L Barrans, PhD, Roger G Owen, Andrew Jack, PhD, MB, Peter Hillmen, MBChB, PhD

Blood (2008) 112 (11): 4178.

https://doi.org/10.1182/blood.V112.11.4178.4178

Published: 2008

NARROW

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

Meta-Analysis of Diffuse Large B-Cell Lymphoma Gene Expression Identifies Novel and Recurrent Biological Connections,

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

A Unified Prognostic Model for Myelodysplastic Syndrome and Acute Myeloid Leukaemia Based on Flow Cytometric Blast Count

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study

TP53 Deletion in CLL: The Significance of Borderline Level Deletion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only